BIOMAT Database Logo BIOMAT Database Logo

Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines. 2019

Hale Samli, and Murat Samli, and Buse Vatansever, and Sena Ardicli, and Nazlihan Aztopal, and Deniz Dincel, and Ahmet Sahin, and Faruk Balci
Department of Genetics, Faculty of Veterinary Medicine, Uludag University, Bursa, Turkey. halesamli@gmail.com.

OBJECTIVE To investigate the expression profiles of 86 miRNAs in paclitaxel-resistant prostate cancer cell lines and to identify the genes that have a role in the development of drug resistance. METHODS Three prostate cancer cell lines, androgen-dependent VCaP, androgen-independent PC-3 and DU-145, were used to obtain paclitaxel-resistant cells by progressively increasing the concentration of paclitaxel in the culture medium. Viability assays with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium and sulforhodamine B were used to assess the cell resistance level and cytotoxic effects of paclitaxel treatment. Total RNA was isolated from both prostate cancer cell lines and their resistant versions, and cDNA samples were reverse transcribed from total RNA. Selected target genes of miRNAs that showed differences in expression and were estimated to be effective on drug resistance mechanism were analyzed with western blot analysis. RESULTS Expression study of 86 miRNAs by RT-PCR demonstrated that several of the miRNAs were expressed at different levels in paclitaxel-resistant cells compared to wild-type cells. Moreover, the expression profiles of these miRNAs varied among different prostate cancer cell line types, with 13 miRNAs being up-regulated in the resistant cells. Among these, miR-200b-3p, miR-34b-3p and miR-375 exhibited a marked up-regulation. Further, miR-100-5p showed a prominent increase in paclitaxel-resistant VCaP-R and DU145-R cells. Western blot and RT-PCR studies showed that only the LARP1 and CCND1 genes were over-expressed up to 2-5 times in all paclitaxel-resistant cell lines compared to the other investigated genes. CONCLUSIONS In this study, the three paclitaxel-resistant prostate cancer cell lines examined showed remarkably different miRNA expression profiles.

UI MeSH Term Description Entries
D008297 Male Males
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D017239 Paclitaxel A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death. 7-epi-Taxol,Anzatax,Bris Taxol,NSC-125973,Onxol,Paclitaxel, (4 alpha)-Isomer,Paxene,Praxel,Taxol,Taxol A,7 epi Taxol,NSC 125973,NSC125973,Taxol, Bris
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D035683 MicroRNAs Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing. RNA, Small Temporal,Small Temporal RNA,miRNA,stRNA,Micro RNA,MicroRNA,Primary MicroRNA,Primary miRNA,miRNAs,pre-miRNA,pri-miRNA,MicroRNA, Primary,RNA, Micro,Temporal RNA, Small,miRNA, Primary,pre miRNA,pri miRNA

Related Publications

Hale Samli, and Murat Samli, and Buse Vatansever, and Sena Ardicli, and Nazlihan Aztopal, and Deniz Dincel, and Ahmet Sahin, and Faruk Balci
The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
June 2007, The Prostate,
Hale Samli, and Murat Samli, and Buse Vatansever, and Sena Ardicli, and Nazlihan Aztopal, and Deniz Dincel, and Ahmet Sahin, and Faruk Balci
The role of the SHH gene in prostate cancer cell resistance to paclitaxel.
August 2014, The Prostate,
Hale Samli, and Murat Samli, and Buse Vatansever, and Sena Ardicli, and Nazlihan Aztopal, and Deniz Dincel, and Ahmet Sahin, and Faruk Balci
Fibronectin Modulates the Expression of miRNAs in Prostate Cancer Cell Lines.
January 2022, Frontiers in veterinary science,
Hale Samli, and Murat Samli, and Buse Vatansever, and Sena Ardicli, and Nazlihan Aztopal, and Deniz Dincel, and Ahmet Sahin, and Faruk Balci
miRNAs differentially expressed in prostate cancer cell lines after soy treatment.
January 2011, In vivo (Athens, Greece),
Hale Samli, and Murat Samli, and Buse Vatansever, and Sena Ardicli, and Nazlihan Aztopal, and Deniz Dincel, and Ahmet Sahin, and Faruk Balci
The role of miRNAs in prostate cancer.
October 2015, European urology,
Hale Samli, and Murat Samli, and Buse Vatansever, and Sena Ardicli, and Nazlihan Aztopal, and Deniz Dincel, and Ahmet Sahin, and Faruk Balci
Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel.
January 2015, Contemporary oncology (Poznan, Poland),
Hale Samli, and Murat Samli, and Buse Vatansever, and Sena Ardicli, and Nazlihan Aztopal, and Deniz Dincel, and Ahmet Sahin, and Faruk Balci
Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs.
January 2021, Biochimica et biophysica acta. Reviews on cancer,
Hale Samli, and Murat Samli, and Buse Vatansever, and Sena Ardicli, and Nazlihan Aztopal, and Deniz Dincel, and Ahmet Sahin, and Faruk Balci
The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines.
January 2023, Frontiers in oncology,
Hale Samli, and Murat Samli, and Buse Vatansever, and Sena Ardicli, and Nazlihan Aztopal, and Deniz Dincel, and Ahmet Sahin, and Faruk Balci
Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines.
May 2020, Cells,
Hale Samli, and Murat Samli, and Buse Vatansever, and Sena Ardicli, and Nazlihan Aztopal, and Deniz Dincel, and Ahmet Sahin, and Faruk Balci
Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
November 1993, The Journal of urology,
Copied contents to your clipboard!